Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00235274 · ClinicalTrials.gov registry record · Phase 2
Effects of RG1068 (Secretin) on Information Processing in Schizophrenia
A Phase 2 study, sponsored by Indiana University.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00235274 is a Phase 2 study that has completed, run by Indiana University. The registered enrollment target is 30 participants.
The verdict
NCT00235274, a Phase 2 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The overarching purpose of the proposed study is to determine Secretin's (RG1068) psychophysiological effects on measures of motor learning, affective, and inhibitory information processing in individuals with schizophrenia. Motor learning will be assessed with a classical eye-blink conditioning procedure, requiring the learning of a reflexive eye-blink response to a weak puff of air to the eye.
Interventions
- DRUG Subcutaneous Secretin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-11 |
| Est. Completion | 2006-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00235274
The ClinicalTrials.gov registry entry for NCT00235274 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Subcutaneous Secretin is the first listed.
NCT00235274 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00235274 about?
NCT00235274 is a clinical study titled "Effects of RG1068 (Secretin) on Information Processing in Schizophrenia". The overarching purpose of the proposed study is to determine Secretin's (RG1068) psychophysiological effects on measures of motor learning, affective, and inhibitory information processing in individuals with schizophrenia. Motor learning will be assessed with a classical eye-blink conditioning pro...
What is the current status of trial NCT00235274?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2005-11. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00235274?
The interventions under investigation include: Subcutaneous Secretin (DRUG).
Who is sponsoring clinical trial NCT00235274?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.